HIGHLIGHTS
- who: Nik Ruzyanei Nik Jaafar from the Medical University of Vienna, Austria have published the research work: Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression, in the Journal: (JOURNAL)
- what: The aim of the case series is to describe the efficacy, tolerability and functional outcome of a novel pharmacological approach involving brexpiprazole as adjunctive treatment to either maintenance intravenous ketamine or intranasal esketamine; in addition to standard biological and psychosocial interventions, in three unipolar and two bipolar TRD patients at an urban public . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.